David Judish, MD
Physical Medicine & Rehabilitation · Puyallup, WANPI 1720030802
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 109 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$364
- Novo Nordisk$336
- Lilly USA, LLC$205
- Myriad Women's Health, Inc.$159
- GSK$147
- Abbott$131
- plus $884 from 19 others
What the payments were for
- Food & beverage$2,227100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $364 |
| Novo Nordisk | 17 | $336 |
| Lilly USA, LLC | 10 | $205 |
| Myriad Women's Health, Inc. | 1 | $159 |
| GSK | 7 | $147 |
| Abbott | 6 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $110 |
| Corcept Therapeutics | 4 | $98 |
| Bayer | 4 | $74 |
| Pfizer | 4 | $73 |
| Medtronic | 3 | $70 |
| Seqirus USA Inc | 3 | $60 |
| Exact Sciences | 3 | $58 |
| Boehringer Ingelheim | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Astellas Pharma US Inc | 2 | $43 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Organon | 2 | $24 |
| Gilead | 1 | $23 |
| AstraZeneca | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Corium, LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$159
How this compares
$2,227 in reported general payments places this provider in the 85th percentile of 260 physical medicine & rehabilitation providers in Washington.
See all physical medicine & rehabilitation providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 51 | $1,239 |
| Baclofen | 72 | $791 |
| Oxycodone Hcl | 14 | $220 |
| Pregabalin | 12 | $155 |
| Tizanidine Hcl | 17 | $135 |
| Trazodone Hcl | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Puyallup
- Nassim RadSeattle$231K
- Nelson HagerTacoma$186K
- Martin ChildersSeattle$170K
- Theodore BrownKirkland$62K
- Angeli MayadevSeattle$51K
- Ronan CahillBellevue$22K
- Karen StanekSpokane$19K
- Beno KuharichSilverdale$17K
- Ib OddersonBellevue$14K
- Wilson ChangIssaquah$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.